Best Menopause Apps That Don't Sell Your Data (2026)

Why Data Selling Is a Real Concern for Menopause Apps

Perimenopause and menopause symptom logs include mood changes, sleep disruption, sexual health data, cognitive symptoms, and irregular bleeding patterns. This is sensitive health data — more sensitive than fitness metrics — and most menopause apps store it on their servers.

The business model of free apps typically involves advertising. Advertising requires data. That creates a structural incentive to share or sell health data to third parties, even when privacy policies say otherwise. The Flo FTC case in 2021 is the clearest documented example of this in the period and menopause app category.

How This List Was Assembled

These apps were assessed on three criteria: where data is stored (on-device vs. server), the monetization model (subscription vs. advertising), and the company’s documented data-sharing history. Apps with regulatory actions or confirmed data-sharing incidents are ranked lower regardless of feature quality.

1. Horiva — On-Device Storage, Nothing to Sell

Horiva stores all symptom data on your device. No data goes to Horiva’s servers. The privacy protection is structural: there is no server-side copy of your health data for anyone to breach, subpoena, or sell.

The app covers 40+ perimenopause symptoms including vasomotor symptoms, cognitive changes, musculoskeletal symptoms, and cycle irregularity. At $9/month it includes a PDF export formatted for GP appointments. A 14-day trial is available with no card required.

2. Clue — GDPR-Bound, No Known Data-Selling Incidents

Clue is based in Berlin and subject to EU GDPR, which imposes stricter limits on data monetization than US law. The company has published data practice documentation and has not faced regulatory action for data sharing.

The free tier is ad-supported, which means usage data informs advertising. The paid tier at $14.99/month removes ads. Clue is a general cycle tracker — perimenopause features exist but the app was not built around the transition.

3. Balance — UK-Based, GDPR-Compliant, Genuine Menopause Focus

Balance was developed with Dr Louise Newson, a UK menopause specialist. The app is UK-based and GDPR-compliant. It has no known data-selling or data-sharing incidents.

The free tier is functional. Premium costs £2.99/month — among the lowest in the category. Data is stored server-side, but the company has a clean record and no ad-based business model.

4. Caria — Subscription Model Removes Ad Incentive

Caria is menopause-specific with community features. The monetization model is subscription-only — no ad revenue — which removes the structural incentive to sell data to advertisers. Data is server-based, and independent privacy audits are not widely documented.

At $9.99/month for the premium tier, Caria is competitively priced relative to Flo and Clue premium.

5. mySysters — Free, No Known Data Issues

mySysters is free with no premium tier. The app has no known data-selling incidents. Feature depth is limited — basic symptom logging without trend analysis, doctor reports, or the symptom library depth of paid apps.

A reasonable starting point if cost is the primary constraint and you are not yet relying on the data for clinical purposes.

6. Menotracker — Free, Basic, Clean Record

Menotracker covers the standard perimenopause symptom checklist and is free with no premium upsell. No known data incidents. The feature set is minimal — adequate for basic logging, not for clinical tracking or trend analysis over a multi-year perimenopause transition.

7. Flo — FTC Settlement, Avoid If Privacy Matters

Flo settled FTC charges in 2021 for sharing sensitive health data — including menstrual and reproductive data — with Facebook, Google, and AppsFlyer without user consent. The settlement required Flo to notify users and submit to third-party audits. It did not require deletion of data already shared.

Flo has updated its stated practices since the settlement. The underlying model — server-based storage, ad-supported free tier — has not changed. For women tracking sensitive perimenopause symptoms, the track record is a legitimate reason to choose an alternative.